Kyntra Bio, Inc.
KYNBHealthcare|Biotechnology|US
$3.73
+0.07 (+1.91%)
DCF Value
$12.09
Cash / Share
$22.56
Financials
Financial Snapshot
Market Cap
$15.1M
Enterprise Value
-$35.5M
Revenue (TTM)
$4.6M
Net Income (TTM)
$183.2M
Cash & Investments
$91.3M
Net Cash
$91.3M
Free Cash Flow (TTM)
-$38.1M
Operating CF (TTM)
-$38.1M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$91.3M
Quarterly Burn
$9.5M
Monthly Burn
$3.2M
Est. Runway
~9.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $253.2M | $735.7M | $621.4M | $533.8M | $686.5M | $405.2M | $422.0M | $235.6M | $50.5M | $89.0M | $91.3M | |
| Operating Cash Flow | $7.1M | -$66.5M | -$76.1M | -$78.7M | $81.6M | -$82.2M | -$145.9M | -$315.0M | -$138.0M | -$4.8M | -$38.1M | |
| Free Cash Flow | $5.9M | -$75.0M | -$84.2M | -$84.5M | $77.6M | -$112.4M | -$184.7M | -$317.5M | -$138.3M | -$4.8M | -$38.1M | |
| Capital Expenditure | -$1.3M | -$8.5M | -$8.0M | -$5.8M | -$4.0M | -$30.2M | -$38.7M | -$2.5M | -$266.0K | -$38.0K | -$9.0K | |
| Financing Cash Flow | $6.7M | $496.5M | $13.9M | -$4.3M | $13.3M | -$563.0K | $46.8M | $122.7M | -$255.0K | -$86.0M | -$85.9M |
R&D Spending
R&D (TTM)
$22.9M
R&D Intensity
495.2%
R&D Growth vs Prior
-2.8%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $179.6M | $125.7M | $213.0M | $256.6M | $176.3M | $235.3M | $140.7M | $46.8M | $29.6M | $6.4M | $4.6M | |
| R&D Expense | $187.2M | $196.5M | $235.8M | $209.3M | $252.9M | $387.0M | $296.8M | $266.5M | $95.7M | $23.5M | $22.9M | |
| R&D % of Revenue | 104.2% | 156.4% | 110.7% | 81.6% | 143.4% | 164.5% | 210.9% | 569.4% | 323.1% | 365.2% | 495.2% | |
| SG&A | $46.0M | $51.8M | $63.8M | $135.5M | $106.4M | $0.00 | $124.7M | $86.5M | $49.3M | $27.7M | $28.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $179.6M | $125.7M | $213.0M | $256.6M | $176.3M | $235.3M | $140.7M | $46.8M | $29.6M | $6.4M | $4.6M | |
| Cost of Revenue | $187.2M | $196.5M | $235.8M | $1.1M | $8.9M | $449.2M | $20.3M | $4.0M | $15.6M | $556.0K | $3.8M | |
| Gross Profit | -$7.6M | -$70.8M | -$22.9M | $255.4M | $167.4M | -$213.9M | $120.5M | $42.8M | $14.1M | $5.9M | $838.0K | |
| R&D | $187.2M | $196.5M | $235.8M | $209.3M | $252.9M | $387.0M | $296.8M | $266.5M | $95.7M | $23.5M | $22.9M | |
| SG&A | $46.0M | $51.8M | $63.8M | $135.5M | $106.4M | $0.00 | $124.7M | $86.5M | $49.3M | $27.7M | $28.2M | |
| Operating Income | -$53.7M | -$122.6M | -$86.7M | -$89.3M | -$191.9M | -$288.5M | -$301.0M | -$322.7M | -$150.4M | -$45.9M | -$50.8M | |
| Interest Expense | $10.7M | $9.7M | $11.0M | $2.9M | $2.4M | $1.1M | $1.4M | $8.1M | $8.2M | $8.8M | $9.3M | |
| Pretax Income | -$61.8M | -$125.9M | -$86.1M | -$76.6M | -$188.9M | -$289.7M | -$293.3M | -$323.2M | -$153.4M | -$58.3M | -$30.9M | |
| Net Income | -$61.7M | -$126.2M | -$86.4M | -$77.0M | -$189.3M | -$290.0M | -$293.7M | -$284.2M | -$47.6M | $183.5M | $183.2M | |
| EPS (Diluted) | -0.98 | -1.73 | -1.03 | -0.89 | -2.11 | -3.15 | -3.15 | -2.92 | -0.48 | 45.37 | 58.19 | |
| EBITDA | -$45.0M | -$104.7M | -$68.6M | -$52.3M | -$164.3M | -$333.7M | -$282.8M | -$305.2M | -$142.4M | -$57.5M | -$94.0M | |
| Shares Out. (M) | 2.51 | 2.92 | 3.36 | 3.47 | 3.59 | 3.69 | 3.74 | 3.89 | 4.00 | 4.04 | 4.05 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $173.8M | $673.7M | $89.3M | $126.3M | $678.4M | $171.2M | $155.7M | $113.7M | $50.5M | $47.9M | $50.6M | |
| Short-Term Investments | $79.4M | $62.1M | $532.1M | $407.5M | $8.1M | $234.0M | $266.3M | $121.9M | $0.00 | $41.1M | $40.7M | |
| Total Current Assets | $266.5M | $749.0M | $690.0M | $702.5M | $755.1M | $474.1M | $492.8M | $331.6M | $196.5M | $99.1M | $96.8M | |
| Total Assets | $469.6M | $898.6M | $880.6M | $857.4M | $826.8M | $773.8M | $610.1M | $423.5M | $214.5M | $119.6M | $101.1M | |
| Total Current Liabilities | $65.1M | $77.3M | $89.0M | $102.7M | $163.2M | $225.5M | $273.6M | $217.7M | $133.3M | $29.2M | $36.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $89.7M | $73.1M | $0.00 | $0.00 | |
| Total Liabilities | $294.4M | $316.2M | $352.1M | $322.0M | $385.4M | $544.7M | $611.6M | $585.7M | $398.2M | $115.1M | $109.2M | |
| Stockholders' Equity | $155.8M | $563.2M | $509.2M | $516.1M | $422.2M | $209.1M | -$21.4M | -$204.2M | -$225.6M | -$30.0M | -$30.1M | |
| Retained Earnings | -$469.7M | -$595.9M | -$715.8M | -$784.7M | -$974.0M | -$1.26B | -$1.56B | -$1.84B | -$1.89B | -$1.71B | -$1.71B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.1M | -$66.5M | -$76.1M | -$78.7M | $81.6M | -$82.2M | -$145.9M | -$315.0M | -$138.0M | -$4.8M | -$38.1M | |
| Capital Expenditure | -$1.3M | -$8.5M | -$8.0M | -$5.8M | -$4.0M | -$30.2M | -$38.7M | -$2.5M | -$266.0K | -$38.0K | -$9.0K | |
| Free Cash Flow | $5.9M | -$75.0M | -$84.2M | -$84.5M | $77.6M | -$112.4M | -$184.7M | -$317.5M | -$138.3M | -$4.8M | -$38.1M | |
| Investing Cash Flow | $6.6M | $69.9M | -$522.1M | $120.0M | $452.5M | -$427.0M | $89.1M | $153.7M | $126.0M | $35.4M | $56.1M | |
| Financing Cash Flow | $6.7M | $496.5M | $13.9M | -$4.3M | $13.3M | -$563.0K | $46.8M | $122.7M | -$255.0K | -$86.0M | -$85.9M | |
| Issuance of Stock | $9.9M | $506.1M | $29.8M | $20.8M | $37.8M | $12.7M | $4.2M | $48.4M | $139.0K | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$69.0K | -$32.0K | |
| Net Debt Issuance | -$403.0K | -$403.0K | -$360.0K | -$12.3M | -$13.0M | -$5.9M | -$538.0K | $73.6M | -$40.0K | -$80.6M | -$80.6M | |
| Stock Based Comp. | $32.1M | $37.5M | $52.1M | $66.3M | $72.7M | $71.2M | $65.6M | $50.8M | $25.2M | $6.6M | $4.0M | |
| Net Change in Cash | $20.5M | $499.9M | -$584.4M | $37.0M | $552.1M | -$507.2M | -$15.5M | -$42.0M | -$11.5M | -$54.3M | -$69.2M |
Dilution Tracker
Shares Outstanding
4M
5-Year Share Growth
+12.5%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2.51 | 2.92 | 3.36 | 3.47 | 3.59 | 3.69 | 3.74 | 3.89 | 4.00 | 4.04 | 4.05 | |
| Change vs Prior % | — | 16.3% | 15.2% | 3.1% | 3.7% | 2.8% | 1.3% | 4.0% | 2.8% | 1.0% | 0.1% | |
| Stock Issuance | $9.9M | $506.1M | $29.8M | $20.8M | $37.8M | $12.7M | $4.2M | $48.4M | $139.0K | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$69.0K | -$32.0K | |
| Stock Based Comp. | $32.1M | $37.5M | $52.1M | $66.3M | $72.7M | $71.2M | $65.6M | $50.8M | $25.2M | $6.6M | $4.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -4.2% | -56.4% | -10.7% | 99.6% | 95.0% | -90.9% | 85.6% | 91.5% | 47.5% | 91.4% | 18.2% | |
| Operating Margin % | -29.9% | -97.6% | -40.7% | -34.8% | -108.8% | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% | -1101.0% | |
| Net Margin % | -34.3% | -100.4% | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% | 3967.8% | |
| EBITDA Margin % | -25.1% | -83.4% | -32.2% | -20.4% | -93.2% | -141.8% | -201.0% | -652.1% | -480.8% | -893.6% | -2036.0% | |
| FCF Margin % | 3.3% | -59.7% | -39.5% | -32.9% | 44.0% | -47.8% | -131.2% | -678.5% | -466.8% | -74.7% | -824.4% | |
| ROE % | -39.6% | -22.4% | -17.0% | -14.9% | -44.8% | -138.7% | 1369.2% | 139.2% | 21.1% | -610.7% | -605.5% | |
| ROA % | -13.1% | -14.0% | -9.8% | -9.0% | -22.9% | -37.5% | -48.1% | -67.1% | -22.2% | 153.4% | 181.2% | |
| ROIC % | -13.3% | -14.9% | -11.0% | -11.6% | -28.3% | -51.6% | -86.8% | -146.6% | -184.9% | -50.7% | -78.2% | |
| R&D / Revenue % | 104.2% | 156.4% | 110.7% | 81.6% | 143.4% | 164.5% | 210.9% | 569.4% | 323.1% | 365.2% | 495.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -0.7% | -30.0% | 69.5% | 20.5% | -31.3% | 33.5% | -40.2% | -66.7% | -36.7% | -78.3% | |
| Gross Profit | 77.1% | -828.7% | 67.7% | 1216.3% | -34.4% | -227.7% | 156.3% | -64.4% | -67.2% | -58.2% | |
| Operating Income | 30.9% | -128.5% | 29.3% | -3.0% | -114.8% | -50.4% | -4.3% | -7.2% | 53.4% | 69.5% | |
| Net Income | 28.1% | -104.6% | 31.5% | 10.9% | -145.9% | -53.2% | -1.3% | 3.2% | 83.3% | 485.6% | |
| EPS (Diluted) | 31.0% | -76.5% | 40.5% | 13.6% | -137.1% | -49.3% | 0.0% | 7.3% | 83.6% | 9552.1% | |
| Operating Cash Flow | 138.3% | -1035.7% | -14.5% | -3.4% | 203.7% | -200.8% | -77.5% | -115.9% | 56.2% | 96.5% | |
| Free Cash Flow | 128.5% | -1381.0% | -12.2% | -0.4% | 191.9% | -244.9% | -64.3% | -71.9% | 56.5% | 96.5% | |
| R&D Expense | -12.6% | 5.0% | 20.0% | -11.3% | 20.9% | 53.0% | -23.3% | -10.2% | -64.1% | -75.4% | |
| SG&A Expense | 3.7% | 12.5% | 23.3% | 112.3% | -21.5% | -100.0% | 0.0% | -30.6% | -43.0% | -43.8% | |
| Total Assets | -0.2% | 91.4% | -2.0% | -2.6% | -3.6% | -6.4% | -21.2% | -30.6% | -49.3% | -44.3% | |
| Book Value / Share | -14.4% | 185.9% | -21.2% | -1.7% | -20.5% | -49.5% | -100.6% | -10440.3% | -10.1% | 102.4% | |
| Debt | 0.3% | 0.4% | -0.6% | -46.6% | -23.4% | 150.8% | -9.9% | 89.6% | -57.1% | -100.0% | |
| Diluted Shares | 4.0% | 16.3% | 15.2% | 3.1% | 3.7% | 2.8% | 1.3% | 4.0% | 2.8% | 1.0% |
Valuation
P/E (TTM)0.06
P/S3.27
10Y Low / Med / High1.79 / 10.65 / 27.53
P/B-0.50
10Y Low / Med / High6.14 / 7.64 / 8.62
EV/EBITDA0.38
EV/Revenue-7.70
10Y Low / Med / High2.55 / 10.18 / 22.95
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$12.09
Cash / Share
$22.56
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -545.92 | -684.97 | -1123.30 | -1204.78 | -439.45 | -111.90 | -127.14 | -7.59 | -27.60 | 0.19 | 0.06 | |
| P/S Ratio | 7.48 | 27.53 | 18.27 | 14.48 | 18.90 | 5.53 | 10.65 | 1.84 | 1.79 | 5.51 | 3.27 | |
| P/B Ratio | 8.62 | 6.14 | 7.64 | 7.20 | 7.89 | 6.23 | -69.90 | -0.42 | -0.24 | -1.18 | -0.50 | |
| EV/EBITDA | -28.15 | -27.53 | -56.86 | -69.61 | -16.40 | -3.69 | -5.07 | -0.47 | -0.53 | 0.22 | 0.38 | |
| EV/Revenue | 7.05 | 22.95 | 18.31 | 14.19 | 15.28 | 5.23 | 10.18 | 3.05 | 2.55 | -1.92 | -7.70 |
Analyst Estimates & Quality
Altman Z-Score
-25.90
Distress
Piotroski F-Score
5
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $6.4M | $7.3M | $7.2M |
| Net Income | -$34.8M | -$40.7M | -$65.6M |
| EPS | $-8.66 | $-9.86 | $-10.07 |
| # Analysts (EPS) | 3 | 3 | 5 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Drug Product Revenue | $8.9M | $962.0K | $11.1M | $18.8M | $27.7M | $5.8M |
| Product | $89.0M | — | — | — | — | — |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| All Other | — | — | — | — | — | — |
| CHINA | $72.5M | $55.6M | $84.6M | $109.4M | $91.0K | — |
| Europe | $67.2M | $131.2M | $33.8M | $9.5M | $6.3M | $5.6M |
| JAPAN | $36.7M | $2.3M | $9.8M | $15.9M | -$2.9M | $797.0K |
| UNITED STATES | — | $46.1M | $12.5M | $13.0M | $26.1M | — |